论文部分内容阅读
目的探讨E838药物对小鼠-肝癌H22的抑瘤效果及合用137Cs γ射线是否具有抑瘤增效作用。方法取小鼠肝癌H22肿瘤组织经研磨用生理盐水稀释成约5×107/ml个肿瘤细胞,接种于小鼠腋下,0.2ml/只。实验分对照组、单放组、E838药物组(5、7.5、10mg/kg)和药物合用照射组及环磷酰胺组。E838各组每日1次ip给药,连续7d;环磷酰胺隔日1次共4次,药物合用照射组于给药的第4天进行全身1Gy照射,每日一次,连续5d。结果E8385、7.5、10mg/kg剂量组对小鼠H22的抑瘤率分别为50.6%、62.73%和54.82%,与对照组比较差异有显著性(P<0.01),小鼠骨髓有核细胞的数量均高于对照组,药物合用137Cs γ射线能提高抑瘤效果,对肿瘤的杀伤作用高于单放组和单药治疗组,抑瘤率分别为52.98%、67.61%和59.15%,结论E838对肝癌H22肿瘤细胞具有明显的抑制作用,合用γ射线具有抑瘤增效作用。
Objective To investigate the antitumor effect of E838 on mouse hepatocarcinoma H22 and whether its combination with 137Cs γ-rays can inhibit tumor growth and synergism. Methods H22 tumor tissues from mice were diluted to about 5 × 10 7 / ml with normal saline and inoculated into the armpit of mice, 0.2 ml / mouse. Experimental control group, single release group, E838 drug group (5,7.5,10 mg / kg) and drug combination irradiation and cyclophosphamide group. Each group of E838 ip once a day for 7 days; cyclophosphamide every other day a total of 4 times, the drug combination irradiation group on the fourth day of administration of systemic 1Gy irradiation once a day for 5 days. Results The inhibitory rates of H22 in mice treated with E8385, 7.5 and 10 mg / kg were 50.6%, 62.73% and 54.82%, respectively, which were significantly different from those of the control group (P <0.01) The results showed that the combination of 137Cs γ-rays with anti-tumor drugs could increase the anti-tumor effect, and the anti-tumor effect was higher than that of single and single drug treatment groups. The inhibition rates of tumor were 52.98%, 67.61% and 59.15% respectively. Conclusion E838 H22 tumor cells of liver cancer has a significant inhibitory effect, combined with γ-rays inhibit tumor synergies.